Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
334.75B
Market cap334.75B
Price-Earnings ratio
35.92
Price-Earnings ratio35.92
Dividend yield
2.63%
Dividend yield2.63%
Average volume
8.83M
Average volume8.83M
High today
$132.53
High today$132.53
Low today
$130.53
Low today$130.53
Open price
$131.06
Open price$131.06
Volume
1.48M
Volume1.48M
52 Week high
$132.53
52 Week high$132.53
52 Week low
$76.66
52 Week low$76.66

Stock Snapshot

As of today, Merck(MRK) shares are valued at $132.45. The company's market cap stands at 334.75B, with a P/E ratio of 35.92 and a dividend yield of 2.63%.

On 2026-07-27, Merck(MRK) stock traded between a low of $130.53 and a high of $132.53. Shares are currently priced at $132.45, which is +1.5% above the low and -0.1% below the high.

Merck(MRK) shares are trading with a volume of 1.48M, against a daily average of 8.83M.

During the past year, Merck(MRK) stock moved between $76.66 at its lowest and $132.53 at its peak.

During the past year, Merck(MRK) stock moved between $76.66 at its lowest and $132.53 at its peak.

MRK News

Simply Wall St 2d
Will Merck’s Early Royalty-Free HIV PrEP Licensing Strategy Redefine Its Global Health Narrative

In July 2026, Merck announced an early, multi-pronged access plan for its investigational once-monthly HIV PrEP pill alimatravir (MK-8527), including royalty-fr...

Will Merck’s Early Royalty-Free HIV PrEP Licensing Strategy Redefine Its Global Health Narrative
TipRanks 2d
Schwab US Dividend Equity ETF Sees Strong Inflows

Schwab US Dividend Equity ETF ( $SCHD ) has risen by 1.65% in the past week. It has experienced a 5-day net inflow of $682.61 million. This is due, in part, to...

TipRanks 3d
Merck announces initial access plans for alimatravir

Merck (MRK) announced early components of a multi-faceted strategy to provide rapid, broad and sustainable access in low- and middle-income countries to alimatr...

Analyst ratings

66%

of 29 ratings
Buy
65.5%
Hold
27.6%
Sell
6.9%

More MRK News

TipRanks 3d
Gilead’s Trodelvy plus Merck’s Keytruda recommended by CHMP in breast cancer

Gilead (GILD) Sciences announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has adopted a posit...

MarketWatch 4d
Merck & Co. Inc. stock outperforms competitors on strong trading day - MarketWatch

...

Merck & Co. Inc. stock outperforms competitors on strong trading day - MarketWatch
Simply Wall St 4d
Merck Gets Fresh KEYTRUDA Momentum In EU Testing And Biliary Cancer Trials

Merck (NYSE:MRK) is seeing new clinical progress for its KEYTRUDA franchise in Europe and in hard to treat cancers. Agilent received EU approval to use its PD-...

Merck Gets Fresh KEYTRUDA Momentum In EU Testing And Biliary Cancer Trials
24/7 Wall St. 4d
Why Retirees Are Choosing This $100.8 Billion ETF Over Individual Dividend Stocks

Why Retirees Are Choosing This $100.8 Billion ETF Over Individual Dividend Stocks By David Beren Published Jul 23, 11:27AM EDT Quick Read SCHD's 3.2% yield co...

Why Retirees Are Choosing This $100.8 Billion ETF Over Individual Dividend Stocks
TipRanks 5d
Merck: ISLEND-Driven HIV Upside Supports Pipeline Re-Rating; Buy Rating Reiterated with Unchanged $141 Price Target

Analyst Jason Gerberry of Bank of America Securities reiterated a Buy rating on Merck & Company, retaining the price target of $141.00. Unlock powerful investi...

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.